Sharemaestro Newsreel

Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over …

Trinity Biotech (TRIB) adds $7M Perceptive funding and cures Nasdaq bid-price issue

Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, …

DFTX News Today | Why did Definium Therapeutics stock go down today?

Labcorp announces executive leadership changes effective in September

Labcorp (NYSE:LH) has announced executive leadership changes effective in September. Megan D. Bailey is resigning as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., will assume an expanded role as Executive Vice President and President, …

Is Lifeward Ltd (LFWD) Positioned for Growth After Q2 Earnings?

Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall

HC Wainwright Issues Negative Forecast for TARA Earnings

AstraZeneca stock trades around $157 as Q2 2026 EPS beats expectations

Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA)

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

MDxHealth SA Stock 12‑Month Price Target Cut to $2.2, Implies 376% Upside

MDxHealth SA's average stock price target has been reduced from $2.8 to $2.2 by analysts, with individual forecasts ranging from $1 to $4. This updated target suggests a potential upside of approximately 376% from its recent closing price. The consensus rating for the stock …

Spectral AI (MDAI): LMR funds report 6.2% beneficial stake via warrants

LMR-affiliated investment entities have reported a 6.2% beneficial ownership stake in Spectral AI, Inc. (MDAI) as of June 30, 2026. This ownership is primarily through warrants exercisable for 2,106,358 shares of Common Stock, with LMR Master Fund and LMR CCSA Master Fund each holding …

Allogene Therapeutics (ALLO) Income Statement & Earnings

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip

PAVmed Inc. (PAVM) reported a narrower GAAP net loss of $5.5 million, or $0.87 per share, in Q2 2026, down from $12.3 million a year earlier, driven by lower non-cash charges. Despite progress in its Lucid Diagnostics, Veris, PortIO, and Octeris programs, the stock …

Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop

Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071

Werewolf Therapeutics Company Profile & Introduction

Bausch Health Stock Gains Momentum as Stronger Earnings, Raised Outlook and Debt Progress Lift Investor Optimism

STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group

A group of investment entities associated with Eli Samaha, collectively known as the Madison Avenue group, has reported a beneficial ownership of 8.4% in STAAR Surgical Company (STAA) as of June 30, 2026. This stake represents 4,175,748 shares of Common Stock out of 49,788,495 …

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share …

Fresenius Medical Care stock steadies around $23 as investors weigh recent buybacks and guidance

Fresenius Medical Care stock is trading steadily around $23 in mid-August 2026, influenced by recent share buybacks and a modest year-to-date decline. The company's capital allocation strategy now includes renewed willingness for buybacks, alongside guidance for continued mid-single-digit revenue growth and improved operating income …

Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock

Ameriprise Financial, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) revealing a 5.8% ownership stake in Personalis, Inc. common stock as of June 30, 2026. This ownership includes shared voting power over 6,054,599 shares and shared dispositive power over 6,086,315 shares. Ameriprise …

Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash …

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …

Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica

Armistice Capital, LLC and Steven Boyd have reported a significant holding in CalciMedica, Inc., disclosing beneficial ownership of 3,411,361 shares, which represents 9.99% of the company's common stock. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

UBS Adjusts Price Target on Acadia Healthcare to $1.50 From $4.50, Keeps Neutral Rating

UBS has adjusted its price target for Acadia Healthcare (referred to as Accendra Health in the article) to $1.50, down from $4.50, while maintaining a Neutral rating on the stock. This adjustment follows similar downgrades and price target reductions from other firms like Citigroup …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7

BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks …

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)